Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myeloid, Acute 6Solid Tumor 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Colorectal Neoplasms 2Urinary Bladder Neoplasms 1Unresectable Colorectal Cancer 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Myeloid Malignancies 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Hematologic Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Azacitidine 66venetoclax 21Decitabine 16Cytarabine 12decitabine and cedazuridine drug combination 10AP 1903 reagent 10Cyclophosphamide 7fludarabine 6pevonedistat 5mocetinostat 5ON 01910 5Busulfan 5treosulfan 4sabatolimab 4ruxolitinib 4cedazuridine 4cc-486 4Mycophenolic Acid 4Lenalidomide 4Injections 4plerixafor 3luspatercept 3imetelstat 3glasdegib 3fludarabine phosphate 3Whole-Body Irradiation 3Methotrexate 3GRN163L peptide 3Clofarabine 3CPX-351 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Myelodysplastic Syndromes × magrolimab × Clear all
NCT05367401 2024-04-11

A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

Novartis

Phase 1/2 Withdrawn
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT02678338 2019-02-21

CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies

Gilead Sciences

Phase 1 Completed
20 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡